MX2023004073A - Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica. - Google Patents
Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica.Info
- Publication number
- MX2023004073A MX2023004073A MX2023004073A MX2023004073A MX2023004073A MX 2023004073 A MX2023004073 A MX 2023004073A MX 2023004073 A MX2023004073 A MX 2023004073A MX 2023004073 A MX2023004073 A MX 2023004073A MX 2023004073 A MX2023004073 A MX 2023004073A
- Authority
- MX
- Mexico
- Prior art keywords
- modulators
- cystic fibrosis
- conductance regulator
- transmembrane conductance
- fibrosis transmembrane
- Prior art date
Links
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 title abstract 4
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D515/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Oscillators With Electromechanical Resonators (AREA)
- Amplifiers (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Esta descripción proporciona moduladores del regulador de la conductancia transmembrana de la fibrosis quística (CFTR) que tienen la estructura central (I), composiciones farmacéuticas que contienen al menos un modulador de este tipo, métodos de tratamiento de enfermedades mediadas por CFTR, que incluyen fibrosis quística, mediante el uso de tales moduladores y composiciones farmacéuticas, composiciones farmacéuticas de combinaciones y terapias combinadas, y procesos y productos intermediarios para producir tales moduladores. (ver Fórmula).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063088799P | 2020-10-07 | 2020-10-07 | |
PCT/US2021/053861 WO2022076625A1 (en) | 2020-10-07 | 2021-10-06 | Modulators of cystic fibrosis transmembrane conductance regulator |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023004073A true MX2023004073A (es) | 2023-07-05 |
Family
ID=78536577
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023004073A MX2023004073A (es) | 2020-10-07 | 2021-10-06 | Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica. |
Country Status (19)
Country | Link |
---|---|
US (1) | US20240018161A1 (es) |
EP (1) | EP4225447A1 (es) |
JP (1) | JP2023545762A (es) |
KR (1) | KR20230104619A (es) |
CN (1) | CN116670143A (es) |
AR (1) | AR123710A1 (es) |
AU (1) | AU2021356651A1 (es) |
BR (1) | BR112023006470A2 (es) |
CA (1) | CA3197173A1 (es) |
CL (1) | CL2023001013A1 (es) |
CO (1) | CO2023005736A2 (es) |
CR (1) | CR20230197A (es) |
DO (1) | DOP2023000065A (es) |
IL (1) | IL301756A (es) |
MX (1) | MX2023004073A (es) |
PE (1) | PE20231951A1 (es) |
TW (1) | TW202229296A (es) |
UY (1) | UY39459A (es) |
WO (1) | WO2022076625A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023150237A1 (en) | 2022-02-03 | 2023-08-10 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
WO2023150236A1 (en) | 2022-02-03 | 2023-08-10 | Vertex Pharmaceuticals Incorporated | Methods of preparing and crystalline forms of (6a,12a)-17-amino-12-methyl-6,15-bis(trifluoromethyl)-13,19-dioxa-3,4,18-triazatricyclo[ 12.3.1.12,5]nonadeca-1(18),2,4,14,16-pentaen-6-ol |
WO2023196429A1 (en) * | 2022-04-06 | 2023-10-12 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2023224931A1 (en) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
WO2024056779A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Crystalline form of (3s,7s,10r,13r)-13-benzyl-20-fluoro-7-isobutyl-n-(2-(3-methoxy-1,2,4-oxadiazol-5-yl)ethyl)-6,9-dimethyl-1,5,8,11-tetraoxo-10-(2,2,2-trifluoroethyl)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-tetradecahydro-[1]oxa[4,7,10,14]tetraazacycloheptadecino[16,17-f]quinoline-3-carboxamide |
WO2024056798A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Macrocyclic cftr modulators |
WO2024056791A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Combination of macrocyclic cftr modulators with cftr correctors and / or cftr potentiators |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
CN101006076B (zh) | 2004-06-24 | 2010-09-29 | 沃泰克斯药物股份有限公司 | Atp-结合弹夹转运蛋白的调控剂 |
SI1945632T1 (sl) | 2005-11-08 | 2014-03-31 | Vertex Pharmaceuticals Incorporated | Heterocikliäśni modulatorji za prenaĺ alce z atp-vezavno kaseto |
JP5409010B2 (ja) | 2005-12-28 | 2014-02-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | N−[2,4−ビス(1,1−ジメチルエチル)−5−ヒドロキシフェニル]−1,4−ジヒドロ−4−オキソキノリン−3−カルボキサミドの固体形態 |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
CA2652072A1 (en) | 2006-05-12 | 2007-11-22 | Vertex Pharmaceuticals Incorporated | Compositions of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
WO2009076142A2 (en) | 2007-12-07 | 2009-06-18 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxiamido-pyridine benzoic acids |
WO2009073757A1 (en) | 2007-12-07 | 2009-06-11 | Vertex Pharmaceuticals Incorporated | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
WO2010019239A2 (en) | 2008-08-13 | 2010-02-18 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
US8716338B2 (en) | 2008-09-29 | 2014-05-06 | Vertex Pharmaceuticals Incorporated | Dosage units of 3-(6-(1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
AU2008363828B2 (en) | 2008-11-06 | 2016-09-08 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
EP2821400B1 (en) | 2009-03-20 | 2017-09-27 | Vertex Pharmaceuticals Incorporated | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
AU2011230508B2 (en) | 2010-03-25 | 2016-04-28 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihyderoxypropyl)-6-fluoro-2- (1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide |
AU2011237368B2 (en) | 2010-04-09 | 2015-07-23 | Ekso Bionics | Exoskeleton load handling system and method of use |
KR20130056244A (ko) | 2010-04-22 | 2013-05-29 | 버텍스 파마슈티칼스 인코포레이티드 | 시클로알킬카르복스아미도-인돌 화합물의 제조 방법 |
AU2011242452A1 (en) | 2010-04-22 | 2012-11-08 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
AU2011293135A1 (en) | 2010-08-27 | 2013-04-11 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
ES2628465T3 (es) | 2011-05-18 | 2017-08-02 | Concert Pharmaceuticals Inc. | Derivados deuterados de ivacaftor |
HUE047354T2 (hu) | 2011-05-18 | 2020-04-28 | Vertex Pharmaceuticals Europe Ltd | Ivacaftor deuterizált származékai |
MX2014010253A (es) | 2012-02-27 | 2014-11-12 | Vertex Pharma | Composicion farmaceutica y administraciones de la misma. |
WO2014014841A1 (en) | 2012-07-16 | 2014-01-23 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof |
MX368353B (es) | 2012-11-02 | 2019-09-30 | Vertex Pharma | Composiciones farmaceuticas para el tratamiento de enfermedades mediadas por cftr. |
WO2014078842A1 (en) | 2012-11-19 | 2014-05-22 | Concert Pharmaceuticals, Inc. | Deuterated cftr potentiators |
PL3925607T3 (pl) | 2014-04-15 | 2023-10-30 | Vertex Pharmaceuticals Incorporated | Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa |
EP3352757B1 (en) | 2015-09-21 | 2023-08-16 | Vertex Pharmaceuticals (Europe) Limited | Administration of deuterated cftr potentiators |
WO2018080591A1 (en) | 2016-10-27 | 2018-05-03 | Vertex Pharmaceuticals (Europe) Limited | Methods of treatment with deuterated cftr potentiators |
US11066417B2 (en) * | 2018-02-15 | 2021-07-20 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators |
AR118555A1 (es) * | 2019-04-03 | 2021-10-20 | Vertex Pharma | Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
US11873300B2 (en) * | 2019-08-14 | 2024-01-16 | Vertex Pharmaceuticals Incorporated | Crystalline forms of CFTR modulators |
-
2021
- 2021-10-06 CR CR20230197A patent/CR20230197A/es unknown
- 2021-10-06 BR BR112023006470A patent/BR112023006470A2/pt unknown
- 2021-10-06 US US18/030,530 patent/US20240018161A1/en active Pending
- 2021-10-06 IL IL301756A patent/IL301756A/en unknown
- 2021-10-06 JP JP2023521522A patent/JP2023545762A/ja active Pending
- 2021-10-06 CN CN202180082146.3A patent/CN116670143A/zh active Pending
- 2021-10-06 MX MX2023004073A patent/MX2023004073A/es unknown
- 2021-10-06 EP EP21805707.3A patent/EP4225447A1/en active Pending
- 2021-10-06 CA CA3197173A patent/CA3197173A1/en active Pending
- 2021-10-06 KR KR1020237015299A patent/KR20230104619A/ko unknown
- 2021-10-06 WO PCT/US2021/053861 patent/WO2022076625A1/en active Application Filing
- 2021-10-06 AU AU2021356651A patent/AU2021356651A1/en active Pending
- 2021-10-06 PE PE2023001368A patent/PE20231951A1/es unknown
- 2021-10-07 UY UY0001039459A patent/UY39459A/es unknown
- 2021-10-07 AR ARP210102780A patent/AR123710A1/es unknown
- 2021-10-07 TW TW110137343A patent/TW202229296A/zh unknown
-
2023
- 2023-04-05 DO DO2023000065A patent/DOP2023000065A/es unknown
- 2023-04-06 CL CL2023001013A patent/CL2023001013A1/es unknown
- 2023-05-05 CO CONC2023/0005736A patent/CO2023005736A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
PE20231951A1 (es) | 2023-12-06 |
WO2022076625A1 (en) | 2022-04-14 |
UY39459A (es) | 2022-05-31 |
JP2023545762A (ja) | 2023-10-31 |
AU2021356651A1 (en) | 2023-05-18 |
CO2023005736A2 (es) | 2023-09-08 |
US20240018161A1 (en) | 2024-01-18 |
KR20230104619A (ko) | 2023-07-10 |
CN116670143A (zh) | 2023-08-29 |
CA3197173A1 (en) | 2022-04-14 |
EP4225447A1 (en) | 2023-08-16 |
CR20230197A (es) | 2023-07-06 |
DOP2023000065A (es) | 2023-07-09 |
TW202229296A (zh) | 2022-08-01 |
BR112023006470A2 (pt) | 2023-09-26 |
CL2023001013A1 (es) | 2023-11-24 |
IL301756A (en) | 2023-05-01 |
AR123710A1 (es) | 2023-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023004073A (es) | Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica. | |
MX2023004072A (es) | Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica. | |
MX2023004074A (es) | Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica. | |
MX2023001465A (es) | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística. | |
MX2022001827A (es) | Moduladores del regulador de conductancia transmembrana de la fibrosis quistica. | |
MX2023005721A (es) | Macrociclos que contienen un anillo de 1,3,4-oxadiazol para su uso como moduladores del regulador de la conductancia transmembrana de la fibrosis quistica. | |
IL189178A0 (en) | Thiazolyl derivatives and pharmaceutical compositions containing the same | |
WO2022032154A3 (en) | Compositions for the delivery of payload molecules to airway epithelium | |
MX2021001903A (es) | Moduladores de regulador de conductancia transmembranal de fibrosis quistica. | |
UY39455A (es) | Moduladores del regulador de conductancia transmembranario de la fibrosis quística | |
MXPA05012317A (es) | Combinaciones terapeuticas de agentes antipsicoticos atipicos con agentes moduladores del gaba anticonvulsivos o benzodiazepinas. | |
AU2021356651A9 (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
MX2020007586A (es) | Proceso de fabricacion de moduladores de somatostatina. | |
CA3196916A1 (en) | Modulators of the integrated stress pathway | |
MX2022009762A (es) | Moduladores del purinorreceptor 3 p2x (p2x3). | |
MX2021011747A (es) | Composiciones y metodos para el tratamiento de la fibrosis quistica. | |
WO2023015318A3 (en) | Genome editing compositions and methods for treatment of cystic fibrosis | |
MX2021008941A (es) | Moduladores gpr35. | |
BR112016029926A2 (pt) | administração nasal | |
WO2023278325A8 (en) | Bifunctional compounds that degrade alk and uses thereof |